Clinical trials are still underway for novel quinazoline derivatives such as zorifertinib, a first-generation EGFR TKI with increased lipophilicity and effectiveness in NSCLC with leptomeningeal metastasis (Figure 1) [90]. Here, EGFR is linked to non-small cell lung carcinoma.